INDGN - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.7
| Stock Code | INDGN | Market Cap | 12,039 Cr. | Current Price | 500 ₹ | High / Low | 633 ₹ |
| Stock P/E | 56.8 | Book Value | 86.4 ₹ | Dividend Yield | 0.40 % | ROCE | 14.3 % |
| ROE | 10.7 % | Face Value | 2.00 ₹ | DMA 50 | 481 ₹ | DMA 200 | 514 ₹ |
| Chg in FII Hold | -1.21 % | Chg in DII Hold | 0.23 % | PAT Qtr | 72.1 Cr. | PAT Prev Qtr | 34.8 Cr. |
| RSI | 59.6 | MACD | 8.75 | Volume | 5,87,375 | Avg Vol 1Wk | 3,19,567 |
| Low price | 414 ₹ | High price | 633 ₹ | PEG Ratio | 3.22 | Debt to equity | 0.03 |
| 52w Index | 39.2 % | Qtr Profit Var | 33.0 % | EPS | 8.80 ₹ | Industry PE | 39.6 |
Core Financials:
Indegene (INDGN) shows moderate fundamentals. ROE is 10.7% and ROCE 14.3%, reflecting average efficiency. EPS at ₹8.80 is modest, though quarterly PAT improved significantly (₹72.1 Cr vs ₹34.8 Cr, +33%). Debt-to-equity is very low at 0.03, indicating a strong balance sheet.
Valuation:
Stock P/E of 56.8 is much higher than industry average (39.6), suggesting overvaluation. PEG ratio of 3.22 highlights stretched growth expectations. Price-to-book is ~5.8, expensive relative to intrinsic value. Dividend yield of 0.40% provides minimal income support.
Business Model & Health:
Indegene operates in healthcare solutions and digital transformation, benefiting from strong demand in pharma and life sciences. Competitive advantage lies in niche expertise and global client base. However, valuations are stretched, and profitability metrics remain moderate.
Entry Zone:
Ideal entry zone: ₹450–₹470. Current price ₹500 is slightly above fair entry. Long-term holding is viable if earnings growth sustains and valuations normalize.
---
Positive
- Strong quarterly PAT growth (+33%)
- Debt-to-equity very low (0.03)
- Technicals show bullish momentum: RSI 59.6, MACD 8.75
- Institutional support from DII (+0.23%)
Limitation
- High P/E (56.8) vs industry (39.6)
- PEG ratio (3.22) suggests overvaluation
- EPS modest at ₹8.80
- Dividend yield negligible (0.40%)
- FII holdings reduced (-1.21%)
Company Negative News
- Valuation concerns due to premium multiples
- Weak EPS relative to price levels
- FII confidence declined
Company Positive News
- Quarterly PAT doubled (₹72.1 Cr vs ₹34.8 Cr)
- DII holdings increased (+0.23%)
- Technical indicators show bullish momentum
Industry
Healthcare and digital transformation sector trades at industry P/E of 39.6, supported by global demand. Indegene trades at a premium due to niche positioning, but profitability metrics are weaker compared to peers.
Conclusion
Indegene is moderately overvalued with niche expertise and strong balance sheet. Rating: 3.7. Entry near ₹450–₹470 is preferable. Long-term holding is viable with a 3–5 year horizon, contingent on sustained earnings growth. Exit strategy around ₹620–₹630 if fundamentals stagnate.
Would you like me to also prepare a peer benchmarking HTML table comparing INDGN with ITC and INOX India, so you can see valuation, ROE, and debt levels side by side?